May 20, 2026 – Artivion, Inc. has closed the transaction to acquire Endospan, a pioneer in endovascular solutions for complex aortic pathologies. The purchase price for the acquisition is $175M, less offsets for previously provided loans, plus a potential for up to $200M in additional consideration contingent upon U.S. NEXUS commercial performance over the next two years.
This follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair.
While Artivion prepares for the full U.S. commercial launch, the acquisition solidifies a market leading position in international markets where Endospan’s technology is already established. Artivion has acted as the exclusive distributor of the NEXUS System in EMEA since 2019. The Endospan expanded portfolio in Europe, Asia-Pacific and Latin America offers a unique breadth of solutions, ranging from off-the-shelf endovascular systems to custom-made multibranch configurations of NEXUS DUO and NEXUS TRE.